Adma Biologics reports Q3 EPS 15c, consensus 16c

Reports Q3 revenue $134.2M, consensus $130.53M. “ADMA is executing from a position of strength as we enter our next phase of disciplined, profitable growth,” said Adam Grossman, President and Chief Executive Officer. “The FDA lot release of our first yield-enhanced production batches marks a pivotal milestone expected to drive sustained gross margin expansion beginning in the fourth quarter of 2025 and through 2026 and beyond. Record ASCENIV utilization and ongoing constructive negotiations with payers for enhanced 2026 reimbursement and access underscore the durable and growing demand for our differentiated plasma-derived biologics portfolio.”